Heart failure & cardiomyopathies
Adherence and Persistence to Pharmacotherapy in Patients with Heart Failure: A Nationwide Cohort Study, 2014–2020
Authors' conclusion
We found low adherence to dual and triple HF therapies in this nationwide cohort study of newly diagnosed HF patients.
Study context
- Population
- Patients aged 18–80 years in Norway with a first heart failure (HF) diagnosis 2014–2020 surviving ≥30 days
- Participants
- 54,899 patients
- Exposure
- Beta-blockers (BB) vs renin-angiotensin system inhibitors (RASi) vs angiotensin receptor-neprilysin inhibitors (ARNI) vs mineralocorticoid receptor antagonists (MRA) vs Dual HF therapy vs Triple HF therapy
- Outcome
- Initiation, 1-year adherence (proportion of days covered (PDC) ≥80%) and long-term persistence (30-day grace period) to BB, RASi and MRA
Methodological detailsregistry-based
- Registry-based
Main finding
As reported in the abstract
Adherence (PDC ≥80%) · first year following initiation
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Initiation | BB 75% · RASi 69% · MRA 21% · Dual HF therapy 61% · Triple HF therapy 16% |
| Persistence, 2 to 5 years following initiation | BB Persistence 2 y → 5 y 58% to 38% · RASi Persistence 2 y → 5 y 57% to 37% · MRA Persistence 2 y → 5 y 31% to 15% |
- Initiation — Did not receive any HF drug
- 13%
Persistence, 2 to 5 years following initiation
- Within RASi, persistence higher for ARNI than for ACEI and ARB
Trends 2014–2019
- No major changes in initiation or adherence, except an increase in initiation and adherence of MRA
Original publication
Adherence and Persistence to Pharmacotherapy in Patients with Heart Failure: A Nationwide Cohort Study, 2014–2020. ESC Heart Fail. Published 20 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →